PDF(Pubmed)
Abstract：
BACKGROUND: Aspergillus fumigatus is a common saprophytic fungus causing allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). The recommended first-line treatment for ABPA is oral steroids, followed by antifungal therapy. However, both treatments are not free from adverse effects; thus, efforts are being made to identify new drugs showing the same effectiveness but with fewer or no side-effects. Therein, biologic drugs have been significantly implemented in clinical practice in treating ABPA in patients with CF.
OBJECTIVE: To systematically review the available literature, providing evidence for the administration of biologic drugs as a new potential treatment of ABPA in both the paediatric and adult populations with CF.
METHODS: A systematic review of the literature published between January 2007 and July 2021 was performed, using a protocol registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42021270932).
RESULTS: A total of 21 studies focusing on the use of biologics in treating ABPA in CF patients was included. We highlighted a paucity of data providing evidence for biologic drug use in ABPA.
CONCLUSIONS: Scientific evidence is insufficient to support firm conclusions and randomised clinical trials are urgently required to investigate the efficacy and safety of biologics for ABPA in CF patients.
OBJECTIVE: To systematically review the available literature, providing evidence for the administration of biologic drugs as a new potential treatment of ABPA in both the paediatric and adult populations with CF.
METHODS: A systematic review of the literature published between January 2007 and July 2021 was performed, using a protocol registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42021270932).
RESULTS: A total of 21 studies focusing on the use of biologics in treating ABPA in CF patients was included. We highlighted a paucity of data providing evidence for biologic drug use in ABPA.
CONCLUSIONS: Scientific evidence is insufficient to support firm conclusions and randomised clinical trials are urgently required to investigate the efficacy and safety of biologics for ABPA in CF patients.
摘要：
背景：烟曲霉是一种常见的腐生真菌，可引起囊性纤维化（CF）患者的过敏性支气管肺曲霉病（ABPA）。ABPA推荐的一线治疗是口服类固醇，其次是抗真菌治疗。然而,两种治疗都没有副作用；因此，正在努力确定具有相同效力但副作用较少或没有副作用的新药。其中,在治疗CF患者ABPA的临床实践中,生物药物已得到显著应用.
目的：为了系统地回顾现有文献，为在患有CF的儿科和成人人群中施用生物药物作为ABPA的新的潜在治疗提供证据。
方法：对2007年1月至2021年7月之间发表的文献进行了系统回顾，使用在国际前瞻性系统审查登记册（PROSPEROCRD42021270932）注册的方案。
结果：共有21项研究集中于使用生物制剂治疗CF患者的ABPA。我们强调了缺乏为ABPA使用生物药物提供证据的数据。
结论：科学证据不足以支持确切的结论，迫切需要随机临床试验来研究生物制剂在CF患者中的疗效和安全性。
目的：为了系统地回顾现有文献，为在患有CF的儿科和成人人群中施用生物药物作为ABPA的新的潜在治疗提供证据。
方法：对2007年1月至2021年7月之间发表的文献进行了系统回顾，使用在国际前瞻性系统审查登记册（PROSPEROCRD42021270932）注册的方案。
结果：共有21项研究集中于使用生物制剂治疗CF患者的ABPA。我们强调了缺乏为ABPA使用生物药物提供证据的数据。
结论：科学证据不足以支持确切的结论，迫切需要随机临床试验来研究生物制剂在CF患者中的疗效和安全性。
